ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The Diabetes Bloc-Stim Neuromodulation system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0 FLEX, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Unternehmens-codeRSLS
Name des UnternehmensReShape Lifesciences Inc
IPO-datumOct 06, 2016
Gegründet am2008
CEOMr. Paul F. Hickey
Anzahl der mitarbeiter17
WertpapierartOrdinary Share
GeschäftsjahresendeOct 06
Addresse1001 Calle Amanecer
StadtSAN CLEMENTE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92673
Telefon19494296680
Websitehttps://www.reshapelifesciences.com/obalon/
Unternehmens-codeRSLS
IPO-datumOct 06, 2016
Gegründet am2008
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten